Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Plus Orthopedics No Longer Facing FDA “Application Integrity” Restrictions

This article was originally published in The Gray Sheet

Executive Summary

Smith & Nephew's new subsidiary Plus Orthopedics was removed from FDA's Application Integrity Policy (AIP) list Sept. 14 after three years of working with the agency to resolve its clinical trial issues

You may also be interested in...



Smith & Nephew Plus: $889 Million Buy Expands European Reconstruction Biz

Smith & Nephew will double its share of the European orthopedic reconstructive implant market with its $889 million acquisition of Plus Orthopedic Holding

Serious Clinical Trial Violations Down In FY 2005 – FDA’s Marcarelli

Device companies showed marked improvement in complying with FDA clinical trial regulations during the past year, according to FDA

Unlucky Breaks Or Compliance Trend? BIMO Spotlight Falls On Orthopedics

FDA has initiated disqualification proceedings against three orthopedic surgeons serving as clinical investigators in the last three months

Related Content

UsernamePublicRestriction

Register

MT025318

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel